BAMS
RARE icon

Bellevue Asset Management (Switzerland)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$1.12M Buy
+10,000
New +$1,000K 0.17% 100

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s RARE Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) opened a new position in Ultragenyx Pharmaceutical (RARE) in Q4 2015: 10,000 shares worth $1.12M. The stake represents 0.17% of the portfolio and ranks #100 among its holdings.

172 funds tracked by Wall St. Rank hold RARE as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 10,000 shares of Ultragenyx Pharmaceutical worth $1.12M as of Q4 2015.
  • Ultragenyx Pharmaceutical was a new Bellevue Asset Management (Switzerland) position in Q4 2015.
  • Ultragenyx Pharmaceutical made up 0.17% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #100 holding.
  • 172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.